Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ChemoCentryx Inc announces positive top-line CCX168 phase II data in ANCA-associated renal vasculitis


Tuesday, 3 Dec 2013 04:05pm EST 

ChemoCentryx Inc:Says positive top-line data from the first two steps of a Phase II trial with CCX168, an inhibitor targeting the chemoattractant receptor known as C5aR, in anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis (AARV).Says AARV is a serious autoimmune disease causing inflammation of the smaller blood vessels. If left untreated, the disease can be fatal. Data from the first two steps. 

Company Quote

7.49
-0.14 -1.83%
22 May 2015